#BIO22: Man­ag­ing a biotech in tur­bu­lent times. 'There's a per­fect shit­show out there'

On Tues­day, June 14, End­points News EIC John Car­roll sat down with a group of biotech ex­ecs to dis­cuss the bear mar­ket for in­dus­try stocks and how they were deal­ing with it. Here’s the con­ver­sa­tion, which has been light­ly edit­ed for brevi­ty.

Mar­tin Mee­son, spon­sor open­ing:

Thank you, John. Hel­lo every­one. My name’s Mar­tin Mee­son, I’m the CEO of Fu­ji­film Diosynth. For those of you who don’t know Fu­ji­film Diosynth, we op­er­ate in the de­vel­op­ment of clin­i­cal and com­mer­cial prod­uct scale up, we have fa­cil­i­ties in Eu­rope and the US, and around about 4,000 em­ploy­ees. We run on av­er­age about 150 pro­grams, so when it comes to man­ag­ing in tur­bu­lent times over the last two years, we’ve had quite a lot of ex­pe­ri­ence of that. Not just keep­ing the clin­i­cal pipelines and the com­mer­cial pipelines open, but al­so our re­sponse to the pan­dem­ic and the mol­e­cules that we’ve had with­in there. One of the phras­es that I coined prob­a­bly about a year ago when we were talk­ing at JP Mor­gan, was I talked about man­ag­ing through tur­bu­lent times. Well, it’s be­come the fact that we are not man­ag­ing and lead­ing through these times, we are man­ag­ing in them, which is why that’s re­al­ly the pur­pose of and the top­ic that we’ve got to­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER